Pharvaris presents deucrictibant data at ACAAI 2026
Phase 3 CHAPTER-3 results show deucrictibant XR cut HAE attack rate by 83% versus placebo, with 45% of participants attack-free over 24 weeks.
See the latest news and media coverage for Pharvaris. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company developing oral therapies for hereditary angioedema
pharvaris.comLast updated
In short: Pharvaris reported positive Phase 3 results for once-daily oral deucrictibant XR in HAE prevention.
Phase 3 CHAPTER-3 results show deucrictibant XR cut HAE attack rate by 83% versus placebo, with 45% of participants attack-free over 24 weeks.
Cash and cash equivalents total €283 million; the deucrictibant IR NDA is under FDA review with a PDUFA date of April 23, 2027.
The pivotal trial met its primary endpoint and all 11 secondary efficacy endpoints, with median symptom relief onset of 1.28 hours versus over 12 hours for placebo. Deucrictibant was generally well tolerated.
Final Phase 2 open-label extension data show a 92.4% average attack reduction and about half of participants attack-free over up to ~34 months, with no safety signals.
Pharvaris' deucrictibant XR reduced HAE attacks by 83% in Phase 3 trials, driving a 23% intraday stock surge on Sept. 8.
Alignment with regulatory agencies following End-of-Phase 2 meetings for the prophylactic development of deucrictibant; global startup activities of CHAPTER-3, pivotal Phase 3 study of deucrictibant...
Pharvaris (NasdaqGS:PHVS) reported positive topline data from its CHAPTER-3 pivotal Phase 3 trial of deucrictibant XR for hereditary angioedema prevention. The study met all primary...
Pharvaris (NASDAQ:PHVS) shares jumped 27% on Tuesday after the company reported positive topline...
Track Pharvaris and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.